/FENC
FENC Stock - Fennec Pharmaceuticals Inc.
Healthcare|BiotechnologyNASDAQ
$7.66+1.06%
+$0.08 (+1.06%) • Dec 19
73
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.39
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.90
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+82.8%upside
Target: $14.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for FENC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$7.58 – $7.74
TARGET (TP)$14.00
STOP LOSS$7.05
RISK/REWARD1:10.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.75
52W High$9.92
52W Low$4.68
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $47.54M | $21.25M | $1.47M | N/A | $170,000 |
| Gross Profit | $44.35M | $19.99M | $1.39M | N/A | $170,000 |
| Gross Margin | 93.3% | 94.1% | 94.4% | N/A | 100.0% |
| Operating Income | $2.57M | $-12,771,000 | $-21,693,963 | $-17,071,455 | $-17,885,000 |
| Net Income | $-436,000 | $-16,045,000 | $-22,774,387 | $-17,193,372 | $-18,109,000 |
| Net Margin | -0.9% | -75.5% | -1544.9% | N/A | -10652.4% |
| EPS | $-0.02 | $-0.60 | $-0.95 | $-0.67 | $-0.76 |
Company Overview
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$12
Average Target
↑ 61.0% Upside
Now
$11
Low
$12
Average
$14
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 22nd 2022 | Cantor Fitzgerald | Upgrade | Overweight | $12← $9 |
| September 7th 2022 | CapitalOne | Initiation | Overweight | $11 |
| August 8th 2022 | Craig Hallum | Resumed | Buy | $14 |
Earnings History & Surprises
FENCBeat Rate
33%
Last 18 quarters
Avg Surprise
-62.1%
EPS vs Estimate
Beats / Misses
6/12
Last 12 quarters
Latest EPS
$-0.02
Q4 2025
EPS Surprise History
Q1 24
-400.0%
$-0.10vs$-0.02
Q2 24
+80.8%
$0.47vs$0.26
Q3 24
-433.3%
$-0.20vs$0.06
Q4 24
-61.5%
$-0.21vs$-0.13
Q1 25
-110.7%
$-0.06vs$0.56
Q2 25
+66.7%
$-0.04vs$-0.12
Q3 25
-83.3%
$-0.11vs$-0.06
Q4 25
+75.0%
$-0.02vs$-0.08
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 9, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | $-0.08 | $-0.02 | +75.0% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-0.06 | $-0.11 | -83.3% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.12 | $-0.04 | +66.7% | ✓ BEAT |
Q1 2025 | Mar 10, 2025 | $0.56 | $-0.06 | -110.7% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.13 | $-0.21 | -61.5% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $0.06 | $-0.20 | -433.3% | ✗ MISS |
Q2 2024 | May 14, 2024 | $0.26 | $0.47 | +80.8% | ✓ BEAT |
Q1 2024 | Mar 21, 2024 | $-0.02 | $-0.10 | -400.0% | ✗ MISS |
Q4 2023 | Nov 6, 2023 | $-0.11 | $-0.07 | +36.4% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.18 | $-0.21 | -16.7% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.21 | $-0.23 | -9.5% | ✗ MISS |
Q1 2023 | Mar 30, 2023 | $-0.24 | $-0.26 | -8.3% | ✗ MISS |
Q4 2022 | Nov 11, 2022 | $-0.17 | $-0.31 | -82.4% | ✗ MISS |
Q3 2022 | Aug 12, 2022 | $-0.10 | $-0.19 | -90.0% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.13 | $-0.14 | -7.7% | ✗ MISS |
Q1 2022 | Feb 28, 2022 | $3.52 | $-0.18 | -105.1% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.18 | $-0.16 | +11.1% | ✓ BEAT |
Q3 2021 | Aug 10, 2021 | $-0.19 | $-0.15 | +21.1% | ✓ BEAT |
Latest News
Fennec Pharmaceuticals Announces City Of Hope Investigator-Sponsored Trial Evaluating PEDMARK To Reduce Cisplatin-Induced Ototoxicity In Adult Men With Stage II–III Metastatic Testicular Germ Cell Tumors
📈 PositiveBenzinga•Dec 9, 2025, 12:06 PM
Fennec Pharmaceuticals Released Topline Results From Phase 2/3 STS-J01 Trial Of Pedmark (Sodium Thiosulfate Injection) For The Reduction Of Cisplatin-induced Ototoxicity In Pediatric And Adolescent And Young Adult Patients With Non-metastatic Solid Tumors In Japan
➖ NeutralBenzinga•Dec 2, 2025, 12:05 PM
Reported Earlier, Fennec Pharmaceuticals Prices Offering Of 4,666,667 Common Shares At $7.50 Per Share For ~$35M In Gross Proceeds
➖ NeutralBenzinga•Nov 14, 2025, 07:35 AM
Fennec Pharmaceuticals Q3 EPS $(0.02), Inline, Sales $12.462M Beat $11.257M Estimate
📈 PositiveBenzinga•Nov 13, 2025, 10:32 PM
Fennec Pharmaceuticals Plans To Launch Common Stock Offering; Terms Not Disclosed
📉 NegativeBenzinga•Nov 13, 2025, 09:09 PM
HC Wainwright & Co. Reiterates Buy on Fennec Pharmaceuticals, Maintains $13 Price Target
📈 PositiveBenzinga•Aug 21, 2025, 02:36 PM
Frequently Asked Questions about FENC
What is FENC's current stock price?
Fennec Pharmaceuticals Inc. (FENC) is currently trading at $7.66 per share. The stock has moved +1.06% today.
What is the analyst price target for FENC?
The average analyst price target for FENC is $14.00, based on 1 analyst.
What sector is Fennec Pharmaceuticals Inc. in?
Fennec Pharmaceuticals Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is FENC's market cap?
Fennec Pharmaceuticals Inc. has a market capitalization of $0.21 billion, making it a small-cap company.
Does FENC pay dividends?
No, Fennec Pharmaceuticals Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAARD
Aardvark Therapeutics, Inc. Common Stock
$13.77
Mkt Cap: $0.3B
AVTX
Avalo Therapeutics, Inc.
$18.60
Mkt Cap: $0.2B
BDTX
Black Diamond Therapeutics, Inc.
$2.54
Mkt Cap: $0.1B
CRBU
Caribou Biosciences, Inc.
$1.68
Mkt Cap: $0.2B
ENTA
Enanta Pharmaceuticals, Inc.
$15.39
Mkt Cap: $0.3B
EPRX
Eupraxia Pharmaceuticals Inc.
$6.56
Mkt Cap: $0.2B
NAUT
Nautilus Biotechnology, Inc.
$1.94
Mkt Cap: $0.2B
OBIO
Orchestra BioMed Holdings, Inc.
$4.35
Mkt Cap: $0.2B
PRLD
Prelude Therapeutics Incorporated
$2.14
Mkt Cap: $0.2B
RNAC
Cartesian Therapeutics, Inc.
$7.22
Mkt Cap: $0.2B
Explore stocks similar to FENC for comparison